Targeting chemotherapy with genetic testing benefits women with aggressive breast cancer

(Institute of Cancer Research) Women with an aggressive form of breast cancer who have faults in their BRCA genes do much better on chemotherapy drug carboplatin than standard treatment, a major clinical trial reports. Researchers found that women with advanced 'triple-negative' breast cancer who had inherited a BRCA mutation were twice as likely to benefit from carboplatin as docetaxel, which is currently standard of care for these patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news